o NoneEntity Type
0001614744
Mainrom Line Logistics Ltd.
Kitov Pharmaceuticals Holdings Ltd.
 
o Corporation
o Limited Partnership
o Limited Liability Company
o General Partnership
o Business Trust
x Other
Limited company
Name of Issuer
 Kitov Pharma Ltd.
Jurisdiction of Incorporation/OrganizationISRAEL 
Year of Incorporation/Organization
  x Over Five Years Ago
  o Within Last Five Years (Specify Year)  
  o Yet to Be Formed 



2. Principal Place of Business and Contact Information
Name of Issuer 
 Kitov Pharma Ltd. 
Street Address 1Street Address 2
 ONE AZRIELI CENTER, ROUND TOWER 132 MENACHEM BEGIN ROAD
CityState/Province/CountryZIP/Postal CodePhone No. of Issuer
 TEL AVIV ISRAEL 6701101 97239333121 



3. Related Persons
Last NameFirst NameMiddle Name
IsraelIsaac
Street Address 1Street Address 2
One Azrieli CenterRound Building
CityState/Province/CountryZIP/Postal Code
Tel AvivISRAEL6701101
Relationship: x Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
 Chief Executive Officer and Director of the Issuer

Last NameFirst NameMiddle Name
RowinskyEric
Street Address 1Street Address 2
One Azrieli CenterRound Building
CityState/Province/CountryZIP/Postal Code
Tel AvivISRAEL6701101
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
 Independent Director and Chairman of the Board of Directors of the Issuer

Last NameFirst NameMiddle Name
RockSimcha
Street Address 1Street Address 2
One Azrieli CenterRound Building
CityState/Province/CountryZIP/Postal Code
Tel AvivISRAEL6701101
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
 Director of the Issuer

Last NameFirst NameMiddle Name
SteinbergSteven
Street Address 1Street Address 2
One Azrieli CenterRound Building
CityState/Province/CountryZIP/Postal Code
Tel AvivISRAEL6701101
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
 Independent Director of the Issuer

 
Last NameFirst NameMiddle Name
AgmonIdo
Street Address 1Street Address 2
One Azrieli CenterRound Building
CityState/Province/CountryZIP/Postal Code
Tel AvivISRAEL6701101
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
 Independent Director of the Issuer

Last NameFirst NameMiddle Name
TzrorRan
Street Address 1Street Address 2
One Azrieli CenterRound Building
CityState/Province/CountryZIP/Postal Code
Tel AvivISRAEL6701101
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
 Independent Director of the Issuer

Last NameFirst NameMiddle Name
Stern-RaffRevital
Street Address 1Street Address 2
One Azrieli CenterRound Building
CityState/Province/CountryZIP/Postal Code
Tel AvivISRAEL6701101
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
 Independent Director of the Issuer

Last NameFirst NameMiddle Name
ReuveniHadas
Street Address 1Street Address 2
One Azrieli CenterRound Building
CityState/Province/CountryZIP/Postal Code
Tel AvivISRAEL6701101
Relationship: x Executive Officer o Director o Promoter
Clarification of Response (if Necessary)
 VP R&D of the Issuer

 
Last NameFirst NameMiddle Name
EfronGil
Street Address 1Street Address 2
One Azrieli CenterRound Building
CityState/Province/CountryZIP/Postal Code
Tel AvivISRAEL6701101
Relationship: x Executive Officer o Director o Promoter
Clarification of Response (if Necessary)
 Deputy CEO and Chief Financial Officer of the Issuer

Last NameFirst NameMiddle Name
LiangBertrand
Street Address 1Street Address 2
One Azrieli CenterRound Building
CityState/Province/CountryZIP/Postal Code
Tel AvivISRAEL6701101
Relationship: x Executive Officer o Director o Promoter
Clarification of Response (if Necessary)
 Chief Medical Officer of the Issuer

Last NameFirst NameMiddle Name
SchicklerMichael
Street Address 1Street Address 2
One Azrieli CenterRound Building
CityState/Province/CountryZIP/Postal Code
Tel AvivISRAEL6701101
Relationship: x Executive Officer o Director o Promoter
Clarification of Response (if Necessary)
 Head of Clinical Operations of the Issuer

 


4. Industry Group
o Agriculture Health Care o Retailing
 Banking & Financial Services   o Biotechnology o Restaurants
  o Commercial Banking   o Health Insurance Technology
  o Insurance  o Hospitals & Physicians  o Computers
  o Investing  x Pharmaceuticals  o Telecommunications
  o Investment Banking  o Other Health Care  o Other Technology
  o Pooled Investment Fund

    Travel
  o Other Banking & Financial Services o Manufacturing  o Airlines & Airports
 Real Estate  o Lodging & Conventions
  o Commercial  o Tourism & Travel Services
  o Construction  o Other Travel
  o REITS & Finance o Other
  o Residential 
  o Other Real Estate 
o Business Services 
 Energy 
  o Coal Mining 
  o Electric Utilities 
  o Energy Conservation 
  o Environmental Services 
  o Oil & Gas 
  o Other Energy 


5. Issuer Size
Revenue RangeAggregate Net Asset Value Range
o No Revenues o No Aggregate Net Asset Value
o $1 - $1,000,000 o $1 - $5,000,000
o $1,000,001 - $5,000,000 o $5,000,001 - $25,000,000
o $5,000,001 - $25,000,000 o $25,000,001 - $50,000,000
o $25,000,001 - $100,000,000 o $50,000,001 - $100,000,000
o Over $100,000,000 o Over $100,000,000
x Decline to Disclose o Decline to Disclose
o Not Applicable o Not Applicable


6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)
o Rule 504(b)(1) (not (i), (ii) or (iii)) o Rule 505
o Rule 504 (b)(1)(i) x Rule 506(b)
o Rule 504 (b)(1)(ii) o Rule 506(c)
o Rule 504 (b)(1)(iii) o Securities Act Section 4(a)(5)
  o Investment Company Act Section 3(c)

7. Type of Filing
x New Notice Date of First Sale 2020-05-24 o First Sale Yet to Occur
o Amendment

8. Duration of Offering
Does the Issuer intend this offering to last more than one year? o Yes x No

9. Type(s) of Securities Offered (select all that apply)
o Pooled Investment Fund Interests x Equity
o Tenant-in-Common Securities o Debt
o Mineral Property Securities o Option, Warrant or Other Right to Acquire Another Security
o Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security o Other (describe)
  


10. Business Combination Transaction
Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? o Yes x No
 
Clarification of Response (if Necessary) 
  

11. Minimum Investment
Minimum investment accepted from any outside investor$ 0 USD

12. Sales Compensation
RecipientRecipient CRD Number x None
 NONE  
(Associated) Broker or Dealer x None(Associated) Broker or Dealer CRD Number x None
    
Street Address 1Street Address 2
 NONE NONE
City State/Province/CountryZIP/Postal Code
 NONE Unknown 00000
State(s) of Solicitation o All States o Foreign/Non-US
 NEW YORK
 

 



13. Offering and Sales Amounts
Total Offering Amount $   USD x Indefinite
Total Amount Sold $ 0 USD 
Total Remaining to be Sold $   USD x Indefinite
 
Clarification of Response (if Necessary)
 Private placements of 812,500 of Filer's ADSs previously issued in June 2020, and 486,111 of Filer's ADSs to be issued in July 2020 to a former placement agent as part of a tail fee in connection with Filer's 2020 offerings.


14. Investors
o Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors,
Number of such non-accredited investors who already have invested in the offering
 
  Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering: 1


15. Sales Commissions & Finders’ Fees Expenses
Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.
Sales Commissions$ 0 USD o Estimate
Finders' Fees$ 0 USD o Estimate
 
Clarification of Response (if Necessary)
  


16. Use of Proceeds
Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.
 $ 0 USD o
Kitov Pharma (NASDAQ:KTOVW)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Kitov Pharma Charts.
Kitov Pharma (NASDAQ:KTOVW)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Kitov Pharma Charts.

Kitov Pharma Ltd. News

Real-Time news about Kitov Pharma Ltd (NASDAQ): 0 recent articles

More Kitov Pharma Ltd. News Articles